Aadi Bioscience (AADI) Scheduled to Post Earnings on Wednesday

Aadi Bioscience (NASDAQ:AADI) is set to release its earnings data before the market opens on Wednesday, November 6th. Analysts expect Aadi Bioscience to post earnings of ($0.46) per share for the quarter.

Aadi Bioscience (NASDAQ:AADI) last posted its earnings results on Wednesday, August 7th. The company reported ($0.54) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.17. The business had revenue of $6.18 million for the quarter, compared to the consensus estimate of $6.33 million. Aadi Bioscience had a negative net margin of 274.77% and a negative return on equity of 66.67%. During the same period last year, the company earned ($0.67) EPS. On average, analysts expect Aadi Bioscience to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Aadi Bioscience Price Performance

Shares of NASDAQ:AADI traded up $0.03 during mid-day trading on Tuesday, hitting $1.99. The company had a trading volume of 16,162 shares, compared to its average volume of 268,330. The firm has a fifty day moving average price of $1.92 and a 200 day moving average price of $1.75. The company has a market capitalization of $49.00 million, a PE ratio of -0.81 and a beta of 0.71. Aadi Bioscience has a one year low of $1.21 and a one year high of $5.70.

Analyst Upgrades and Downgrades

AADI has been the topic of several recent research reports. HC Wainwright reaffirmed a “neutral” rating on shares of Aadi Bioscience in a report on Wednesday, August 21st. Piper Sandler lowered Aadi Bioscience from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $5.00 to $1.75 in a research report on Tuesday, August 27th. TD Cowen downgraded Aadi Bioscience from a “buy” rating to a “hold” rating in a report on Wednesday, August 21st. Jefferies Financial Group cut Aadi Bioscience from a “buy” rating to a “hold” rating and lowered their price objective for the company from $11.00 to $1.50 in a research report on Wednesday, August 21st. Finally, Piper Sandler Companies downgraded Aadi Bioscience from an “overweight” rating to a “neutral” rating and set a $1.75 target price for the company. in a research report on Tuesday, August 27th. Five analysts have rated the stock with a hold rating, According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $10.25.

Insider Activity

In other Aadi Bioscience news, Chairman Neil Desai sold 40,000 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $1.71, for a total transaction of $68,400.00. Following the sale, the chairman now owns 1,171,543 shares in the company, valued at $2,003,338.53. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 37.30% of the company’s stock.

About Aadi Bioscience

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.